As Sanofi looks to step up its vaccine manufacturing game by the middle of the decade, the French Big Pharma is wading into the virtual world.
Adding another layer of tech to its forthcoming “EVolutive” vaccine facilities in France and Singapore, Sanofi is tapping Dassault Systèmes’ simulated 3D spaces to optimize production through the power of the digital twin.
Dassault’s platform creates a digitized environment where Sanofi will be able to “experience the manufacturing systems under development and their operation virtually,” helping establish its processes “before deploying them,” the partners explained in a press release.
These sorts of simulations, known as digital or virtual twins, are essentially computerized copies of real-world objects or processes. Experts can use live, digital copies to garner real-time insights on a range of topics.
The process of qualifying new facilities, equipment and production processes can take pharmaceutical manufacturers weeks or months, Dassault said. But digital twins “enable manufacturers to standardize modules, reduce this timeframe, and boost their ability to quickly and massively produce crucial therapies,” the digital twin specialist says.
As of April, Sanofi had plugged around 900 million euros into the pair of boundary-pushing EVolutive factories, which it has pegged to help “pave the way for future vaccine innovation across the world.
Back in 2020, Sanofi unveiled plans for the French facility, which it said would be constructed over a period of five years.
Work kicked off on the Singapore branch this spring, with the aim to wrap up the project by the end of 2025.
Aside from vaccines, Sanofi’s EVolutive plants are being designed to crank out a range of biologic platforms, including mRNA, enzymes and monoclonal antibodies, the company has said.
By Fraiser Kansteiner
Source: fiercepharma.com
Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.
The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.
Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.
